In the Claims

Please amend the claims according to the claim listing provided below.

Marked-Up Copy of Claims:

1. (original) A compound of Formula (I):



(I)

or pharmaceutically acceptable salt thereof, wherein:

X is O, S, SO, SO_2, CO, COO, NR^7, $CONR^7$, $SONR^7$, SO_2NR^7, NR^7CONR^7 or is absent;

Y is C_1-C_{10} alkylenyl or is absent, wherein Y is optionally substituted by halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, hydroxy, carboxy, amino, alkylamino, or dialkylamino;

Z is O, S, SO, SO_2 or absent;

R^1 is H, C_1-C_8 alkyl, C_3-C_7 cycloalkyl, or C_1-C_8 haloalkyl;

R^2 is C_1-C_8 alkyl or C_1-C_8 haloalkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

or R^2 and R^3 together with the C atom to which they are attached form a C_3-C_7 cycloalkyl ring;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, mercapto, C_1-C_8 alkoxy, C_1-C_8 thioalkoxy, C_1-C_8 haloalkoxy, aryloxy, cycloalkyloxy, heteroaryloxy, heterocycloalkyloxy, cyano, nitro, NR^8R^9, NR^8COR^{10}, COR^{10}, $COOR^{11}$, or $CONR^8R^9$;

R^7 is H, C_1-C_4 alkyl, or C_1-C_4 haloalkyl;

R^8 and R^9 are each, independently, H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl;

or R^8 and R^9 together with the N atom to which they are attached form a 5- or 6-membered heterocycloalkyl group;

R^{10} is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl;

R^{11} is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl;

Ar is aryl or heteroaryl, each optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_3-C_7 cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, mercapto, C_1-C_6 thioalkoxy, C_3-C_7 thiocycloalkyloxy, thioaryloxy, thioheteroaryloxy, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, C_1-C_4 haloalkylsulfinyl, C_1-C_4 haloalkylsulfonyl, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$, $NR^{14}COR^{12}$, $NR^{14}CONR^{14}R^{15}$, or $CONR^{14}R^{15}$;

or Ar together with Y and Z form a benzo-fused cycloalkyl or benzo-fused heterocycloalkyl group, each optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_3-C_7 cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, mercapto, C_1-C_6 thioalkoxy, C_3-C_7 thiocycloalkyloxy, thioaryloxy, thioheteroaryloxy, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, C_1-C_4 haloalkylsulfinyl, C_1-C_4 haloalkylsulfonyl, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$, $NR^{14}COR^{12}$, $NR^{14}CONR^{14}R^{15}$, or $CONR^{14}R^{15}$;

R^{12} is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl;

R^{13} is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl; and

R^{14} and R^{15} are each, independently, H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl;

or R^{14} and R^{15} together with the N atom to which they are attached form a 5- or 6-membered heterocycloalkyl group,

with the provisos:

a) when Ar-Z-Y-X- is bonded at position 7 or 8, and X is O, S or NR^7; Y is unsubstituted C_1-C_{10} alkylenyl or absent; and Z is absent, then Ar is substituted;

b) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is aryl or aryl substituted with 1 substituent selected from the group consisting of C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy, then said aryl is further substituted with one

substituent other than a substituent from the group consisting of C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy;

c) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is aryl substituted with 2 substituents selected from C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy, then said aryl is further substituted with at least one substituent;

d) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is heteroaryl or heteroaryl substituted with 1 substituent selected from the group consisting of halogen and C_{1-8} alkyl, then said heteroaryl is further substituted with one substituent other than a substituent from the group consisting of halogen and C_{1-8} alkyl; and

e) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is heteroaryl substituted with 2 substituents selected from halogen and C_{1-8} alkyl, then said heteroaryl is further substituted with at least one substituent.

2. (original) The compound of claim 1 wherein X is O, NR^7, $CONR^7$, or absent.

3. (original) The compound of claim 1 wherein X is CO.

4. (original) The compound of claim 1 wherein Ar is phenyl.

5. (original) The compound of claim 1 wherein R^1 is H.

6. (original) The compound of claim 1 wherein R^2 is C_1-C_4 alkyl.

7. (original) The compound of claim 1 wherein R^2 is methyl.

8. (original) The compound of claim 1 wherein R^3 is H.

9. (original) The compound of claim 1 wherein R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, or hydroxy.

10. (original) The compound of claim 1 having Formula (**IIa**):



(IIa)

or pharmaceutically acceptable salt thereof.

11. (original) The compound of claim 10 wherein:

wherein:

X is O, CO, S, SO, SO_2, NR^7, $CONR^7$ or is absent;

Y is C_1-C_6 alkylenyl or is absent, wherein Y is optionally substituted by halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, hydroxy, carboxy, amino, alkylamino, or dialkylamino;

Z is O, S, or absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_8 haloalkoxy; and

Ar is phenyl or pyridyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$;

or Ar together with Y and Z form a benzo-fused cycloalkyl or benzo-fused heterocycloalkyl group, each optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_3-C_7 cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, mercapto, C_1-C_6 thioalkoxy, C_3-C_7 thiocycloalkyloxy, thioaryloxy, thioheteroaryloxy, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, C_1-C_4 haloalkylsulfinyl, C_1-C_4 haloalkylsulfonyl, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$, $NR^{14}COR^{12}$, $NR^{14}CONR^{14}R^{15}$, or $CONR^{14}R^{15}$.

12. (original) The compound of claim 10 wherein:

X is CO;

Y is C_1-C_8 alkylenyl or absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_4 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_4 haloalkoxy; and

Ar is phenyl substituted by one or more halo, cyano, nitro, C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_4 alkoxy, or C_1-C_6 haloalkoxy.

13. (original) The compound of claim 10 wherein:

X is NR^7;

Y is C_1-C_6 alkylenyl;

Z is absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_4 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_8 haloalkoxy; and

Ar is phenyl substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$;

or Ar together with Y and Z form a benzo-fused cycloalkyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$.

14. (original) The compound of claim 10 wherein:

X is $CONR^7$;

Y is C_1-C_6 alkylenyl or is absent;

Z is absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_4 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_8 haloalkoxy; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$.

15. (original) The compound of claim 10 wherein:

X is absent;

Y is C_1-C_6 alkylenyl;

Z is absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_4 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_8 haloalkoxy; and

Ar is phenyl or pyridyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$.

16. (original) The compound of claim 1 having Formula (**IIb**):



(IIb)

or pharmaceutically acceptable salt thereof.

17. (original) The compound of claim 16 wherein:

X is O, NR^7, or is absent;

Y is C_1-C_6 alkylenyl or is absent, wherein Y is optionally substituted by halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, hydroxy, carboxy, amino, alkylamino, or dialkylamino;

Z is O, S, or absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is H;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, mercapto, C_1-C_8 alkoxy, C_1-C_8 thioalkoxy, C_1-C_8 haloalkoxy, aryloxy, cycloalkyloxy, heteroaryloxy, heterocycloalkyloxy, cyano, nitro, NR^8R^9, NR^8COR^{10}, COR^{10}, $COOR^{11}$, or $CONR^8R^9$; and

Ar is phenyl or pyridyl, each optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_3-C_7 cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, mercapto, C_1-C_6 thioalkoxy, C_3-C_7 thiocycloalkyloxy, thioaryloxy, thioheteroaryloxy, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, C_1-C_4 haloalkylsulfinyl, C_1-C_4 haloalkylsulfonyl, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$, $NR^{14}COR^{12}$, $NR^{14}CONR^{14}R^{15}$, or $CONR^{14}R^{15}$.

18. (original) The compound of claim 16 wherein:

X is absent;

Y is methylene or ethylene;

Z is absent;

R^1 is H or C_1-C_4 alkyl;

R^2 is methyl or ethyl;

R^3 is H;

R^4 and R^6 are both H;

R^5 is halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, hydroxy, C_1-C_8 alkoxy, C_1-C_8 haloalkoxy, cyano, nitro, or NR^8R^9; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, or $NR^{14}R^{15}$.

19. (original) The compound of claim 16 wherein:

X is O;

Y is methylene or ethylene;

Z is O or absent;

R^1 is H or C_1-C_4 alkyl;

R^2 is methyl or ethyl;

R^3 is H;

R^4 and R^6 are both H;

R^5 is halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, hydroxy, C_1-C_8 alkoxy, C_1-C_8 haloalkoxy, cyano, nitro, or NR^8R^9; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, or $NR^{14}R^{15}$.

20. (original) The compound of claim 1 having Formula (**IId**):



(IId)

or pharmaceutically acceptable salt thereof.

21. (original) The compound of claim 20 wherein:

X is absent;

Y is methylene or ethylene;

Z is absent;

R^1 is H or C_1-C_4 alkyl;

R^2 is methyl or ethyl;

R^3 is H;

R^4 and R^5 are both H;

R^6 is halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, hydroxy, C_1-C_8 alkoxy, C_1-C_8 haloalkoxy, cyano, nitro, or NR^8R^9; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, or $NR^{14}R^{15}$.

22. (original) The compound of claim 1 selected from:

a) 1-methyl-8-(2-phenoxy-ethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) (4-fluoro-benzyl)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

c) biphenyl-4-ylmethyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

d) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid phenylamide;

e) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid benzylamide;

f) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid phenethylamide;

g) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid phenpropylamide;

h) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid 4-phenylbenzylamide;

i) [2-(3,4-dimethoxy-phenyl)-ethyl]-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

j) 8-benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

k) indan-1'-yl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

l) 7-benzyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

m) 8-benzyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and

n) 6-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol;

or pharmaceutically acceptable salt thereof.

23. (original) The compound of claim 1 selected from:

a) 8-(3-Methoxy-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) 8-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

c) 8-Benzyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

d) 8-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol;

e) 1-Methyl-8-phenethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

f) 8-(2-Fluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

g) 8-(3-Fluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

h) 8-(4-Fluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

i) 1-Methyl-8-(3-trifluoromethyl-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

j) 8-(2,6-Difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

k) 8-(2,4-difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

l) 8-(2,5-Difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

m) 8-(3,5-difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

n) 8-(3,4-Difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

o) 8-(2-Methoxy-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

p) 8-(4-Methoxy-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

q) 1-Methyl-8-(1-phenyl-ethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

r) (8-Methoxy-5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-methanone;

s) (5-Methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-methanone;

t) 6-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol;

u) 8-Benzyl-7-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

v) 8-(3-Fluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol; and

w) 7-(3-Fluoro-benzyloxy)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

or pharmaceutically acceptable salts.

24. (amended) A composition comprising a compound of claim 1~~any one of claims 1 to 23~~ and a pharmaceutically acceptable carrier.

25. (amended) A method of treating disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, sleep apnea or HDL-related condition comprising administering to a patient in need of said treating a therapeutically effective amount of a compound of claim 1~~any one of claims 1 to 23~~.

26. (original) The method of claim 25 wherein the disorders of the central nervous system are selected from depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

27. (original) The method according to claim 25 wherein the disorder of the central nervous system is obesity.

28. (original) The method according to claim 25 wherein the sexual dysfunction is male erectile dysfunction.

29. (amended) A method of decreasing food intake of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1~~any one of claims 1 to 23~~.

30. (amended) A method of inducing satiety in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1~~any one of claims 1 to 23~~.

31. (amended) A method of controlling weight gain of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1~~any one of claims 1 to 23~~.

32. (amended) A method of treating obesity comprising administering to a patient in need of such treating a therapeutically effective amount of a compound of claim 1~~any one of claims 1 to 23~~.

Claims 33 to 47 are cancelled

48. (new) A method for preparing a pharmaceutical composition comprising the step of mixing a compounds of claim 1 and a pharmaceutically acceptable carrier.

Clean Copy of Claims:

1. (original) A compound of Formula (I):



(I)

or pharmaceutically acceptable salt thereof, wherein:

X is O, S, SO, SO_2, CO, COO, NR^7, $CONR^7$, $SONR^7$, SO_2NR^7, NR^7CONR^7 or is absent;

Y is C_1-C_{10} alkylenyl or is absent, wherein Y is optionally substituted by halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, hydroxy, carboxy, amino, alkylamino, or dialkylamino;

Z is O, S, SO, SO_2 or absent;

R^1 is H, C_1-C_8 alkyl, C_3-C_7 cycloalkyl, or C_1-C_8 haloalkyl;

R^2 is C_1-C_8 alkyl or C_1-C_8 haloalkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

or R^2 and R^3 together with the C atom to which they are attached form a C_3-C_7 cycloalkyl ring;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, mercapto, C_1-C_8 alkoxy, C_1-C_8 thioalkoxy, C_1-C_8 haloalkoxy, aryloxy, cycloalkyloxy, heteroaryloxy, heterocycloalkyloxy, cyano, nitro, NR^8R^9, NR^8COR^{10}, COR^{10}, $COOR^{11}$, or $CONR^8R^9$;

R^7 is H, C_1-C_4 alkyl, or C_1-C_4 haloalkyl;

R^8 and R^9 are each, independently, H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl;

or R^8 and R^9 together with the N atom to which they are attached form a 5- or 6-membered heterocycloalkyl group;

R^{10} is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl;

R^{11} is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl;

Ar is aryl or heteroaryl, each optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_3-C_7 cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, mercapto, C_1-C_6 thioalkoxy, C_3-C_7 thiocycloalkyloxy, thioaryloxy, thioheteroaryloxy, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, C_1-C_4 haloalkylsulfinyl, C_1-C_4 haloalkylsulfonyl, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$, $NR^{14}COR^{12}$, $NR^{14}CONR^{14}R^{15}$, or $CONR^{14}R^{15}$;

or Ar together with Y and Z form a benzo-fused cycloalkyl or benzo-fused heterocycloalkyl group, each optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_3-C_7 cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, mercapto, C_1-C_6 thioalkoxy, C_3-C_7 thiocycloalkyloxy, thioaryloxy, thioheteroaryloxy, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, C_1-C_4 haloalkylsulfinyl, C_1-C_4 haloalkylsulfonyl, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$, $NR^{14}COR^{12}$, $NR^{14}CONR^{14}R^{15}$, or $CONR^{14}R^{15}$;

R^{12} is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl;

R^{13} is H, C_1-C_4 alkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl, or heterocycloalkyl; and

R^{14} and R^{15} are each, independently, H, C_1-C_4 alkyl, C_1-C_4 haloalkyl, C_3-C_7 cycloalkyl, cycloalkylalkyl, aryl, or arylalkyl;

or R^{14} and R^{15} together with the N atom to which they are attached form a 5- or 6-membered heterocycloalkyl group,

with the provisos:

a) when Ar-Z-Y-X- is bonded at position 7 or 8, and X is O, S or NR^7; Y is unsubstituted C_1-C_{10} alkylenyl or absent; and Z is absent, then Ar is substituted;

b) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is aryl or aryl substituted with 1 substituent selected from the group consisting of C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy, then said aryl is further substituted with one substituent other than a substituent from the group consisting of C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy;

c) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is aryl substituted with 2 substituents selected from C_{1-8} alkyl, halogen, perhaloalkyl, and alkoxy, then said aryl is further substituted with at least one substituent;

d) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is heteroaryl or heteroaryl substituted with 1 substituent selected from the group consisting of halogen and C_{1-8} alkyl, then said heteroaryl is further substituted with one substituent other than a substituent from the group consisting of halogen and C_{1-8} alkyl; and

e) when Ar-Z-Y-X- is bonded at position 7 or 8, and X, Y and Z are absent, and Ar is heteroaryl substituted with 2 substituents selected from halogen and C_{1-8} alkyl, then said heteroaryl is further substituted with at least one substituent.

2. (original) The compound of claim 1 wherein X is O, NR^7, $CONR^7$, or absent.

3. (original) The compound of claim 1 wherein X is CO.

4. (original) The compound of claim 1 wherein Ar is phenyl.

5. (original) The compound of claim 1 wherein R^1 is H.

6. (original) The compound of claim 1 wherein R^2 is C_1-C_4 alkyl.

7. (original) The compound of claim 1 wherein R^2 is methyl.

8. (original) The compound of claim 1 wherein R^3 is H.

9. (original) The compound of claim 1 wherein R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, or hydroxy.

10. (original) The compound of claim 1 having Formula (**IIa**):



(IIa)

or pharmaceutically acceptable salt thereof.

11. (original) The compound of claim 10 wherein:

wherein:

X is O, CO, S, SO, SO_2, NR^7, $CONR^7$ or is absent;

Y is C_1-C_6 alkylenyl or is absent, wherein Y is optionally substituted by halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, hydroxy, carboxy, amino, alkylamino, or dialkylamino;

Z is O, S, or absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_8 haloalkoxy; and

Ar is phenyl or pyridyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$;

or Ar together with Y and Z form a benzo-fused cycloalkyl or benzo-fused heterocycloalkyl group, each optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_3-C_7 cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, mercapto, C_1-C_6 thioalkoxy, C_3-C_7 thiocycloalkyloxy, thioaryloxy, thioheteroaryloxy, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, C_1-C_4 haloalkylsulfinyl, C_1-C_4 haloalkylsulfonyl, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$, $NR^{14}COR^{12}$, $NR^{14}CONR^{14}R^{15}$, or $CONR^{14}R^{15}$.

12. (original) The compound of claim 10 wherein:

X is CO;

Y is C_1-C_8 alkylenyl or absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_4 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_4 haloalkoxy; and

Ar is phenyl substituted by one or more halo, cyano, nitro, C_1-C_4 alkyl, C_1-C_4 haloalkyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_4 alkoxy, or C_1-C_6 haloalkoxy.

13. (original) The compound of claim 10 wherein:

X is NR^7;

Y is C_1-C_6 alkylenyl;

Z is absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_4 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_8 haloalkoxy; and

Ar is phenyl substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$;

or Ar together with Y and Z form a benzo-fused cycloalkyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$.

14. (original) The compound of claim 10 wherein:

X is $CONR^7$;

Y is C_1-C_6 alkylenyl or is absent;

Z is absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_4 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_8 haloalkoxy; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$.

15. (original) The compound of claim 10 wherein:

X is absent;

Y is C_1-C_6 alkylenyl;

Z is absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_4 alkyl;

R^3 is H, C_1-C_8 alkyl, or C_1-C_8 haloalkyl;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_4 alkyl, C_1-C_4 haloalkyl, hydroxy, mercapto, C_1-C_4 alkoxy, or C_1-C_8 haloalkoxy; and

Ar is phenyl or pyridyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$.

16. (original) The compound of claim 1 having Formula (**IIb**):



(**IIb**)

or pharmaceutically acceptable salt thereof.

17. (original) The compound of claim 16 wherein:

X is O, NR^7, or is absent;

Y is C_1-C_6 alkylenyl or is absent, wherein Y is optionally substituted by halo, C_1-C_4 alkyl, C_1-C_4 alkoxy, C_1-C_4 haloalkyl, C_1-C_4 haloalkoxy, hydroxy, carboxy, amino, alkylamino, or dialkylamino;

Z is O, S, or absent;

R^1 is H or C_1-C_8 alkyl;

R^2 is C_1-C_8 alkyl;

R^3 is H;

R^4, R^5, and R^6 are each, independently, H, halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, C_2-C_8 alkenyl, C_2-C_8 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, mercapto, C_1-C_8 alkoxy, C_1-C_8 thioalkoxy, C_1-C_8 haloalkoxy, aryloxy, cycloalkyloxy,

heteroaryloxy, heterocycloalkyloxy, cyano, nitro, NR^8R^9, NR^8COR^{10}, COR^{10}, $COOR^{11}$, or $CONR^8R^9$; and

Ar is phenyl or pyridyl, each optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, aryl, heteroaryl, C_3-C_7 cycloalkyl, heterocycloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, C_3-C_7 cycloalkyloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, mercapto, C_1-C_6 thioalkoxy, C_3-C_7 thiocycloalkyloxy, thioaryloxy, thioheteroaryloxy, C_1-C_4 alkylsulfinyl, C_1-C_4 alkylsulfonyl, C_1-C_4 haloalkylsulfinyl, C_1-C_4 haloalkylsulfonyl, COR^{12}, $COOR^{13}$, $NR^{14}R^{15}$, $NR^{14}COR^{12}$, $NR^{14}CONR^{14}R^{15}$, or $CONR^{14}R^{15}$.

18. (original) The compound of claim 16 wherein:

X is absent;

Y is methylene or ethylene;

Z is absent;

R^1 is H or C_1-C_4 alkyl;

R^2 is methyl or ethyl;

R^3 is H;

R^4 and R^6 are both H;

R^5 is halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, hydroxy, C_1-C_8 alkoxy, C_1-C_8 haloalkoxy, cyano, nitro, or NR^8R^9; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, or $NR^{14}R^{15}$.

19. (original) The compound of claim 16 wherein:

X is O;

Y is methylene or ethylene;

Z is O or absent;

R^1 is H or C_1-C_4 alkyl;

R^2 is methyl or ethyl;

R^3 is H;

R^4 and R^6 are both H;

R^5 is halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, hydroxy, C_1-C_8 alkoxy, C_1-C_8 haloalkoxy, cyano, nitro, or NR^8R^9; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, or $NR^{14}R^{15}$.

20. (original) The compound of claim 1 having Formula **(IId)**:



(IId)

or pharmaceutically acceptable salt thereof.

21. (original) The compound of claim 20 wherein:

X is absent;

Y is methylene or ethylene;

Z is absent;

R^1 is H or C_1-C_4 alkyl;

R^2 is methyl or ethyl;

R^3 is H;

R^4 and R^5 are both H;

R^6 is halo, C_1-C_8 alkyl, C_1-C_8 haloalkyl, hydroxy, C_1-C_8 alkoxy, C_1-C_8 haloalkoxy, cyano, nitro, or NR^8R^9; and

Ar is phenyl optionally substituted by one or more halo, cyano, nitro, C_1-C_6 alkyl, C_1-C_6 haloalkyl, hydroxy, C_1-C_6 alkoxy, C_1-C_6 haloalkoxy, or $NR^{14}R^{15}$.

22. (original) The compound of claim 1 selected from:

a) 1-methyl-8-(2-phenoxy-ethoxy)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) (4-fluoro-benzyl)-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

c) biphenyl-4-ylmethyl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

d) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid phenylamide;

e) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid benzylamide;

f) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid phenethylamide;

g) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid phenpropylamide;

h) 5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine-7-carboxylic acid 4-phenylbenzylamide;

i) [2-(3,4-dimethoxy-phenyl)-ethyl]-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

j) 8-benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

k) indan-1'-yl-(5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-amine;

l) 7-benzyl-8-chloro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

m) 8-benzyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; and

n) 6-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol;

or pharmaceutically acceptable salt thereof.

23. (original) The compound of claim 1 selected from:

a) 8-(3-Methoxy-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

b) 8-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

c) 8-Benzyl-7-methoxy-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

d) 8-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol;

e) 1-Methyl-8-phenethyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

f) 8-(2-Fluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

g) 8-(3-Fluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

h) 8-(4-Fluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

i) 1-Methyl-8-(3-trifluoromethyl-benzyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

j) 8-(2,6-Difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

k) 8-(2,4-difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

l) 8-(2,5-Difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

m) 8-(3,5-difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

n) 8-(3,4-Difluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

o) 8-(2-Methoxy-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

p) 8-(4-Methoxy-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

q) 1-Methyl-8-(1-phenyl-ethyl)-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

r) (8-Methoxy-5-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-methanone;

s) (5-Methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yl)-phenyl-methanone;

t) 6-Benzyl-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol;

u) 8-Benzyl-7-fluoro-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine;

v) 8-(3-Fluoro-benzyl)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-ol; and

w) 7-(3-Fluoro-benzyloxy)-1-methyl-2,3,4,5-tetrahydro-1H-benzo[d]azepine; or pharmaceutically acceptable salts.

24. (amended) A composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

25. (amended) A method of treating disorders of the central nervous system, damage to the central nervous system, cardiovascular disorders, gastrointestinal disorders, diabetes insipidus, sleep apnea or HDL-related condition comprising administering to a patient in need of said treating a therapeutically effective amount of a compound of claim 1.

26. (original) The method of claim 25 wherein the disorders of the central nervous system are selected from depression, atypical depression, bipolar disorders, anxiety disorders, obsessive-compulsive disorders, social phobias or panic states, sleep disorders, sexual dysfunction, psychoses, schizophrenia, migraine and other conditions associated with cephalic pain or other pain, raised intracranial pressure, epilepsy, personality disorders, age-related behavioral disorders, behavioral disorders associated with dementia, organic mental disorders, mental disorders in childhood, aggressivity, age-related memory disorders, chronic fatigue syndrome, drug and alcohol addiction, obesity, bulimia, anorexia nervosa and premenstrual tension.

27. (original) The method according to claim 25 wherein the disorder of the central nervous system is obesity.

28. (original) The method according to claim 25 wherein the sexual dysfunction is male erectile dysfunction.

29. (amended) A method of decreasing food intake of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.

30. (amended) A method of inducing satiety in a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.

31. (amended) A method of controlling weight gain of a mammal comprising administering to said mammal a therapeutically effective amount of a compound of claim 1.

32. (amended) A method of treating obesity comprising administering to a patient in need of such treating a therapeutically effective amount of a compound of claim 1.

Claims 33 to 47 are cancelled

48. (new) A method for preparing a pharmaceutical composition comprising the step of mixing a compounds of claim 1 and a pharmaceutically acceptable carrier.